MedTrace Logo

Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab

NCT04138420 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2019-10-24

No results posted yet for this study

Summary

This study evaluates the retinal and vascular features in patients with macular degeneration under the effects of Bevacizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.

Conditions

  • Exudative Age-related Macular Degeneration

Interventions

DRUG

Bevacizumab Injection

Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Gilda Cennamo, MD · Federico II University

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-25
Primary Completion
2017-10-25
Completion
2017-10-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04138420 on ClinicalTrials.gov